Chart Of The Day: Eli Lilly - Big Profits In Big Pharma -

Chart Of The Day: Eli Lilly – Big Profits In Big Pharma

Oct 26, 2023Jeremy ParkinsonFinance0

The Chart of the Day belongs to the pharmaceutical giant Eli Lilly (LLY). I found the stock by using Barchart’s powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. LLY Price vs Daily Moving AveragesEli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.Barchart’s Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. Barchart Technical Indicators:

100% technical buy signals

73.30+ Weighted Alpha

67.31% gain in the last year

Trend Seeker buy signal

Above its 20, 50 and 100 day moving averages

7 new highs and up 6.42% in the last month

Relative Strength Index 54.82%

Technical support level at $582.85

Recently traded at $586.37 with 50 day moving average of $567.75

Fundamental Factors:

Market Cap $562 billion

P/E 73.93

Dividend yield .74%

Revenue expected to grow 17.50% this year and another 16.70% next year

Earning estimated to increase an additional 88.10% next year and continue to compound at an annual rate of 26.75% for the next 5 years

Analysts and Investor Sentiment — I don’t buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it’s hard to make money swimming against the tide:

Wall Street analyst gave15 strong buy, 4 buy, 5 hold and 3 sell opinions on the stock

Analysts’ price targets are between $340 and $710 with a consensus of $604

The individual investors following the stock on Motley Fool voted 1,255 to 103 for the stock to beat the market with the more experienced investors voting 318 to 14 for the same result

Value Line rates it an above average 2

CFRAs MarketScope rates it 4 star buy with a price target of $634

More By This Author:Chart Of The Day: Walmart – Still A Bargain
Chart Of The Day: Microsoft Still Looks Great!
Chart Of The Day: Google – By Any Other Name Is Still Sweet